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Site-selective protein modiﬁcation via disulﬁde
rebridging for fast tetrazine/trans-cyclooctene
bioconjugation†
Lujuan Xu,a,b Marco Raabe, a,b Maksymilian M. Zegota,a,b João C. F. Nogueira,c
Vijay Chudasama, c Seah Ling Kuan *a,b and Tanja Weil *a,b
An inverse electron demand Diels–Alder reaction between tetrazine and trans-cyclooctene (TCO) holds
great promise for protein modiﬁcation and manipulation. Herein, we report the design and synthesis of a
tetrazine-based disulﬁde rebridging reagent, which allows the site-selective installation of a tetrazine
group into disulﬁde-containing peptides and proteins such as the hormone somatostatin (SST) and the
antigen binding fragment (Fab) of human immunoglobulin G (IgG). The fast and eﬃcient conjugation of
the tetrazine modiﬁed proteins with three diﬀerent TCO-containing substrates to form a set of bioconju-
gates in a site-selective manner was successfully demonstrated for the ﬁrst time. Homogeneous, well-
deﬁned bioconjugates were obtained underlining the great potential of our method for fast bioconjuga-
tion in emerging protein therapeutics. The formed bioconjugates were stable against glutathione and in
serum, and they maintained their secondary structure. With this work, we broaden the scope of tetrazine
chemistry for site-selective protein modiﬁcation to prepare well-deﬁned SST and Fab conjugates with
preserved structures and good stability under biologically relevant conditions.
Introduction
Peptides and proteins are emerging as powerful treatment
options, as exemplified by the application of antibodies and
antibody fragments (Fab) in immunotherapy and antibody–
drug conjugates in targeted cancer therapy.1 Nevertheless,
protein stability, immunogenicity and the time required to
engineer recombinant antibodies could limit their develop-
ment for in vivo studies.2 In this regard, nature has evolved an
optimal synthetic factory in the form of posttranslational pro-
cesses, in which diverse functionalities can be attached to pro-
teins in a site-directed fashion.3 Inspired by this, chemists
strive to develop methodologies to impart diverse functional-
ities to native proteins with similar levels of precision.
Site-selective modification of therapeutically relevant pep-
tides and proteins to introduce reactive bioorthogonal handles
has emerged for post-modification in an “on-demand” fashion
to expand the features and functions of proteins to address the
challenges in fundamental biological and medical appli-
cations.4 In this manner, protein therapeutics can be syntheti-
cally customized to program their properties for envisaged
applications.
Over the past decades, several bioorthogonal reactions,
including the [3 + 2] azide–alkyne cycloaddition, photoclick
1,3-dipolar cycloaddition and the inverse electron demand
Diels–Alder (IEDDA) reactions, have been developed and
applied for protein modifications.5 Among these, the IEDDA
reaction of 1,2,4,5-tetrazine with trans-cyclooctene (TCO)
stands out, providing fast reaction kinetics (rate constant of up
to 106 M−1 s−1), excellent orthogonality, catalyst-free con-
ditions and good biocompatibility, and is a widely employed
bioorthogonal approach in chemical biology.6 Previously, the
IEDDA reaction has been applied for the preparation of anti-
body conjugates, mainly via statistical modifications using
N-hydroxysuccinimide (NHS) ester chemistry for cell imaging,7
nanoparticle functionalization,8 and antibody targeted
therapy.6a,9 In the literature, two common approaches to site-
selectively modify proteins utilizing the IEDDA reaction are,
the introduction of a diene or dienophile by genetic code
expansion methods via the incorporation of noncanonical
amino acids10 and tag-based posttranslational attachment
strategies using enzymes (e.g. lipoic acid protein ligase A).11
Nevertheless, the genetic code expansion method suﬀers from
low yields and tedious synthesis. This in turn limits its scal-
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ability and accessibility for further applications, while tag-
based posttranslational attachment strategies first require the
genetic fusion of a specific peptide sequence (e.g. lipoate
acceptor peptide) to the protein of interest.11 A single tetrazine
or TCO group has also been introduced site-selectively into
peptides or proteins at an unpaired cysteine site via the thiol-
maleimide reaction.6a,12
However, very few native proteins contain free cysteine resi-
dues.13 Furthermore, thiol–maleimide chemistry easily under-
goes the retro-Michael reaction resulting in a maleimide
exchange with other reactive thiols present, for example gluta-
thione, under physiological conditions causing oﬀ-target
eﬀects.4a Therefore, other methods, which can introduce a
tetrazine or TCO group in a site-selective fashion into proteins
for subsequent IEDDA reactions are highly desirable to expand
the scope of their applications. Since many therapeutically
relevant peptides and proteins contain at least one disulfide
bond close to the protein surface, the disulfide rebridging
strategy provides a versatile technique to modify the solvent
accessible disulfide bonds on these proteins and peptides to
install suitable bioorthogonal tags.13,14 Smith and coworkers
presented an elegant approach to introduce the tetrazine
group at the disulfide site of proteins/peptides via dichloro-
tetrazine.15 However, a significantly reduced activity of the
protein was reported after the modification. In this context, di-
sulfide modification based on bis-alkylating reagents to form
bisthioether conjugates gained wide applications for site-selec-
tive protein modifications without compromising their bio-
activity. Furthermore, it has been reported that bisthioether
conjugates formed by disulfide rebridging are more stable
than thiol-maleimide conjugates16 suggesting that it could be
a viable strategy for the installation of IEEDA reaction handles.
Herein, we present a simple and straightforward method for
the site-selective incorporation of a tetrazine group into native
peptides and proteins through disulfide rebridging with the
allyl sulfone scaﬀold reported previously.17 In comparison
with known bis-sulfone disulfide rebridging reagents, allyl
sulfone reagents provide improved reactivity and higher water
solubility, which greatly facilitates protein bioconjugations.17
The disulfide rebridging reactions of allyl sulfones proceed
in situ without side reactions e.g. with reducing agents
such as tris(2-carboxyethyl)-phosphine hydrochloride (TCEP).
In comparison, disubstituted maleimide disulfide rebridging
reagents, such as 3,4-dibromomaleimide, show side reactions
with TCEP, presumably due to the nucleophilic addition of
phosphine to the electron-poor alkene moiety.18 The versatility
of the method was demonstrated by modifying two model sub-
strates: SST and IgG Fab under mild conditions which yielded
a set of well-defined protein conjugates (Fig. 1). The formed
protein conjugates showed good stability and maintained
their secondary structures after bioconjugation. The reported
methodology provides a rapid, robust and straightforward
strategy for site-selective protein labeling and expands the scope
of using IEDDA chemistry in the functionalization of thera-
peutically relevant peptides and proteins in a precise manner.
Results and discussion
Synthesis and characterization of the tetrazine-based disulfide
rebridging reagent
For the site-selective installation of bioorthogonal handles on
the proteins, a longer incubation time (usually overnight) is
often required.13 Therefore, the diene “6-methyl-1,2,4,5-tetra-
zine” instead of the dienophile “TCO” was introduced into the
protein. This strategy fully utilizes the fast kinetics of the
IEDDA reaction but minimizes the inherent isomerization
issues of TCO to nonreactive cis-cyclooctene, which occurs at a
longer incubation time or in the presence of thiols.4c,19 In this
context, a tetrazine-based allylsulfone disulfide rebridging
reagent (IC-Tetrazine, Scheme 1) was designed and readily
Fig. 1 Schematic overview of site-selective incorporation of a reactive tetrazine tag into a solvent-accessible disulﬁde site of a cell-targeting
peptide or antibody fragment. The tetrazine-modiﬁed peptide/protein is used for post-functionalization to construct a small set of protein bioconju-
gates with a (1) dye, (2) polymer and (3) protein in a fast and highly selective manner with high conversions (one isomer is shown as a
representation).
Scheme 1 Synthesis of the tetrazine-containing disulﬁde rebridging
reagent (IC-Tetrazine). (a) Di-tert-butyl dicarbonate, CH2Cl2, overnight.
(b) Methacryloyl chloride, Et3N, CH2Cl2, 90%. (c) 1. I2, sodium p-toluene-
sulﬁnate, CH2Cl2, 3 days. 2. Et3N, CH2Cl2, overnight. 3. Et3N, ethyl
acetate, 95 °C, overnight, ﬁnal yield: 60%. (d) Triﬂuoroacetic acid (TFA),
CH2Cl2, 98%. (e) Methyltetrazine NHS ester, Et3N, CH2Cl2, overnight,
40%.
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obtained through a four-step synthesis. As shown in Scheme 1,
tetraethylene glycol monoamine (1) was protected to aﬀord 2-
(2-boc-aminoethoxy)ethanol (2) that underwent condensation
with methacryloyl chloride yielding the corresponding meth-
acrylate derivative (3). After a tandem iodosulfonylation–dehy-
droiodination reaction, the tosyl group was introduced to form
allyl-sulfone (4). The tert-butoxycarbonyl group was sub-
sequently removed in an acidic medium to aﬀord the primary
amino group, which then reacted with methyl-tetrazine NHS
ester to aﬀord the IC-Tetrazine reagent.
Site-selective protein modification
Subsequently, two model substrates (somatostatin and human
IgG Fab) were selected for site-selective modification with
IC-Tetrazine. Somatostatin (SST) regulates the endocrine
system and mediates signal transduction via five G protein-
coupled receptors (SSTR) that are overexpressed in high levels
in various kinds of cancer cells and tumor blood vessels.20 SST
conjugates have been widely investigated for targeted drug
delivery into SSTR-expressing cancer cells.20,21 IC-Tetrazine
was reacted with SST after its single accessible disulfide bond
was reduced to generate free thiol groups by the addition of
two equivalents of TCEP at room temperature (Fig. 2a). The
product (SST-Tetrazine) was purified by high-performance
liquid chromatography (HPLC) yielding SST-Tetrazine in 30%
yield, which is comparable to that reported in the literature
(20% to 40%).13 Characterization by matrix assisted laser de-
sorption/ionization time of flight mass spectrometry
(MALDI-TOF-MS) revealed two signals corresponding to the
desired SST-Tetrazine (m/z = 2110.95 [M + H]+, Fig. 2b, the
molecular weight of native SST is 1637 g mol−1) and the laser
fragmentation species of SST-Tetrazine (m/z = 2041.93, the
chemical structure of the fragmentation species is shown in
Fig. S3†), respectively. Notably, SST-Tetrazine is stable for more
than one year when stored as a solid at −20 °C (Fig. S4†).
Next, we applied the modification method to an antibody
fragment (Fab) from human immunoglobulin G (IgG). Fab
fragments have been successfully used for constructing anti-
body–drug and antibody–nanoparticle conjugates providing
several advantages compared to the complete antibody.22 The
conjugate retains the antigen-binding region which is crucial
for active targeting, but circumvents the non-specific binding
of the Fc region of antibodies.22a Since the interchain disul-
fides are much more exposed to the solvent and less stable
relative to the intrachain disulfides that are buried between
the two layers of anti-parallel β-sheet structures,23 IgG Fab was
incubated with 50 equivalents of TCEP (optimization of the
amounts of TCEP is shown in Fig. S5†) to reduce the solvent
accessible interchain disulfide bonds and subsequently
reacted with IC-Tetrazine overnight (Fig. 2a). The tetrazine
modified Fab fragment (Fab-Tetrazine) was purified by ultrafil-
tration to remove residual TCEP and IC-Tetrazine. The
MALDI-TOF-MS analysis of Fab-Tetrazine revealed a molecular
weight of 48.5 kDa (Fig. 2c), showing an increase of ∼500 Da
compared to that of the native Fab (48.0 kDa, Fig. S5B†)
demonstrating its successful site-selective modification.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) of Fab-Tetrazine revealed a single band at ∼48 kDa
showing that only a slight reduction occurred after site-selec-
tive modification even in the presence of 100 equivalents of
TCEP after one hour (Fig. 2d, band 2). In contrast, under the
same conditions, the native IgG Fab was almost completely
reduced exhibiting a single band appearing at ∼24 kDa on
SDS-PAGE (Fig. 2d, band 1). Based on the concentration calcu-
Fig. 2 (a) Site-selective modiﬁcation of SST and IgG Fab with IC-Tetrazine. (b) MALDI-TOF-MS spectrum of SST-Tetrazine (found: 2110.95 [M + H]+,
calculated: 2110.95 [M + H]+). The m/z peak at 2041.93 corresponds to the fragmentation of SST-Tetrazine. (c) MALDI-TOF-MS spectrum of Fab-
Tetrazine (Fab-Tetrazine: found: 48.5k [M + H]+, calculated: 48.5k [M + H]+). (d) SDS-PAGE analysis of native Fab and Fab-Tetrazine (M: Applichem
Protein Marker VI, 1: Fab (native) + 100 eq. TCEP incubation for one hour, and 2: Fab-Tetrazine + 100 eq. TCEP incubation for one hour).
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lated from gel densitometry (Fig. 2d), about 80% of the Fab
fragment was successfully modified. A thiol quantification
experiment using the thiol reagent 4,4′-dithiodipyridine was
performed and the result showed that about 73% of IgG Fab
were successfully modified, which is consistent with the result
obtained from gel densitometry (details are shown in the ESI,
Fig. S5c†). Taken together, the results clearly indicated that the
disulfide bonds in IgG Fab were successfully rebridged using
IC-Tetrazine.
Bioconjugation with a chromophore, PEG and enzyme
The versatility of the tetrazine-modified SST and IgG Fab for
the construction of well-defined bioconjugates was demon-
strated through post-modification with a fluorophore (cyanine-
5, Cy5) and a PEG chain. In addition, SST-Tetrazine was also
conjugated to a protein enzyme (cytochrome C, CytC) to form
a peptide–protein conjugate with high conversion. A TCO-ter-
minated PEG chain of a precise chain length with 12 repeating
units (TCO-PEG12) was selected to facilitate the characteriz-
ation by MALDI-TOF-MS. TCO-PEG12 was incubated with
SST-Tetrazine in phosphate buﬀer (PB, 50 mM, pH = 7.4) and
the pink color of the tetrazine group disappeared immediately
after mixing, indicating that the reaction took place instan-
taneously. The bioconjugation reaction was carried out for
30 minutes to ensure completion. Thereafter, the reaction
mixture was injected into the HPLC column and a predomi-
nant peak of SST-PEG12 was obtained (Fig. S7, ESI†).
SST-PEG12 was isolated in nearly quantitative yield (95%) and
characterized by MALDI-TOF-MS (Fig. 3b). SST-Tetrazine was
also conjugated to TCO-Cy5 under similar conditions yielding
the desired conjugate SST-Cy5 in 90% yield. MALDI-TOF-MS
showed the m/z signal at 3041.17 (Fig. 3c).
Due to the much larger molecular weight of Fab-Tetrazine
compared to SST-Tetrazine, a longer PEG chain with a mole-
cular weight of 5000 Da containing 113 repeating units on
average (TCO-PEG113) was incubated with Fab-Tetrazine in
phosphate buﬀer (pH = 7.4) for 30 minutes to aﬀord Fab-
PEG113. The characteristic band of Fab-Tetrazine at ∼48 kDa
almost entirely disappeared after PEGylation and a new band
emerged, which was broader due to the polydispersity of the
PEG chain (Fig. 3d). A control experiment of mixing native Fab
and TCO-PEG113 did not show any unspecific absorption on
SDS-PAGE (Fig. 3d). MALDI-TOF-MS spectra revealed a signal
at 53.5 kDa indicating the successful conjugation (Fig. S11D†).
Under similar conditions, the widely applied chromophore
Cy5 was also attached to Fab-Tetrazine to aﬀord Fab-Cy5 (mole-
cular weight: 49.5 kDa, Fig. 3e) in 73% yield (the calculation is
shown in the ESI†). Successful conjugation was confirmed by
an increase in the molecular weight of ∼1.5 kDa in the
MALDI-TOF-MS spectra in comparison with those of native
Fab (molecular weight: 48 kDa, Fig. 3e).
CytC is a 12 kDa hemeprotein typically located in the mito-
chondria of viable cells.24 Iso-yeast CytC has a single thiol
group on its surface for modification via thiol-maleimide
chemistry.25 TCO-PEG3-maleimide was reacted with CytC to
introduce the TCO group via thiol-maleimide chemistry
aﬀording CytC-PEG3-TCO (Scheme S4†). MALDI-TOF-MS data
revealed the successful modification of CytC (Fig. S6, ESI†). In
addition, a tetrazine-based dye (tetrazine-5-fluorescein,
Tetrazine-FAM, excitation wavelength: 492 nm and emission
Fig. 3 (a) Bioconjugation between (i) SST-Tetrazine with TCO-PEG12 and TCO-Cy5. (ii) Fab-Tetrazine with TCO-Cy5 and TCO-PEG113 via a fast
click reaction. (b) MALDI-TOF-MS spectrum of SST-PEG12 (found: 2852.21 [M + H]+, calculated: 2852.28 [M + H]+). (c) MALDI-TOF-MS spectrum of
SST-Cy5 (found: 3041.17 [M + H]+, calculated: 3041.28 [M + H]+). Sinapic acid was used as the matrix for all MALDI-TOF-MS measurements. (d)
SDS-PAGE analysis of Fab-PEG113 (M: Applichem Protein Marker VI, 1: Fab-Tetrazine, and 2: Fab + TCO-PEG113, 3: Fab-PEG113). (e) MALDI-TOF-MS
spectra of Fab-Cy5 (found: 49.5k [M + H]+, calculated: 49.5k [M + H]+) and native Fab (found: 48.0k [M + H]+, calculated: 48.0k [M + H]+).
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wavelength: 517 nm) was used to react with CytC-PEG3-TCO to
assess the modification yield of CytC. Based on the absorbance
of CytC at 280 nm and the FAM dye at 490 nm, about 90% of
CytC was successfully modified with the TCO group (experi-
mental details are shown in the ESI†). Thereafter, the targeting
peptide SST-Tetrazine was conjugated to CytC-PEG3-TCO by
mixing and shaking for 30 minutes.
After ultrafiltration to remove the residual SST-Tetrazine,
SST-PEG3-CytC was obtained and characterized by
MALDI-TOF-MS and SDS-PAGE. In the MALDI-TOF-MS spectra,
the signal at 15 315 Da corresponds to the desired SST-PEG3-
CytC conjugate (Fig. 4b), whereas the signal for CytC-PEG3-
TCO (13 233 Da) completely disappeared. On SDS-PAGE, a
slight band shift was observed indicating the successful conju-
gation between SST-Tetrazine and CytC-PEG3-TCO (Fig. 4c).
The conjugation of Fab-Tetrazine with CytC-PEG3-TCO was
also performed. However, MALDI-Tof-MS data showed almost
no conjugation product, presumably due to the steric hin-
drance of the two bulky macromolecules.
Stability studies of SST-Tetrazine, Fab-Tetrazine and Fab-Cy5
The stability of the bioconjugates after disulfide modification
is an important consideration for their intended applications
in cellular environments. Therefore, the stability of the modi-
fied protein with the newly synthesized disulfide rebridging
reagent in glutathione (GSH) was investigated using liquid
chromatography mass spectrometry (LC-MS). SST-Tetrazine
(10 µM) was incubated with two-fold excess of GSH at biologi-
cally relevant concentrations (20 μM)26 at 37 °C and
SST-Tetrazine and the degradation product (GSH-Tetrazine,
1085 [M + H]+; the chemical structure is shown in Scheme S9†)
were identified by simultaneous detection by UV-Vis spec-
troscopy at an absorption wavelength of 254 nm and selective
ion monitoring (SIM). The amount of SST-Tetrazine in each
sample was determined as a ratio of the integration of the
chromatogram at 254 nm of SST-Tetrazine to the standard
(Fmoc-L-phenylalanine) (Fig. 5a and b). LC-MS data showed
that SST-Tetrazine remained intact after 24 hours of incu-
bation and no degradation products were detected in the SIM
profile (Fig. S12C†). Next, the stability of the Fab conjugates
was investigated based on the literature protocol.22b Fab-
Tetrazine and Fab-Cy5 were incubated with 1% fetal bovine
serum (FBS) at 37 °C and monitored using SDS-PAGE.
SDS-PAGE data revealed no change in Fab-Tetrazine after
24 hours, indicating no obvious degradation (Fig. 5c). The
stability of Fab-Cy5 was also investigated based on the quanti-
fication of the fluorescence of the conjugate (shown in the
ESI,† page 15). The data indicated a good stability of Fab-Cy5
after incubation with FBS for 24 hours (Fig. 5d). Taken
together, these experiments showed that the resultant peptide
and protein bioconjugates formed by the disulfide rebridging
strategy and the subsequent IEDDA reaction remained stable
under physiological conditions, e.g. in the presence of GSH or
in media containing serum proteins.
Fig. 4 (a) Bioconjugation between SST-Tetrazine and CytC-PEG3-TCO.
(b) MALDI-TOF-MS spectrum of SST-PEG3-CytC (found: 15 315 [M +
H]+, calculated: 15 314 [M + H]+) matrix: sinapic acid. (c) SDS-PAGE ana-
lysis of SST-PEG3-CytC (M: Applichem Protein Marker VI, 1: CytC-PEG3-
TCO, and 2: SST-PEG3-CytC).
Fig. 5 (a) Stability study of SST-Tetrazine via LC-MS. (b) Area ratio of SST-Tetrazine at 254 nm compared to Fmoc-L-phenylalanine (standard) at
three time points (n = 3, values are given as mean ± SD). (c) Stability study of Fab-Tetrazine by SDS-PAGE (M: Applichem Protein Marker VI, 1: Fab-
Tetrazine, 2: 1% FBS, 3: Fab-Tetrazine + 1% FBS incubated for 12 hours, and 4: Fab-Tetrazine + 1% FBS incubated for 24 hours), (d) Stability study of
Fab-Cy5 by SDS-PAGE with (left) and without (right) Coomassie blue (M: Applichem Protein Marker VI, 1: 1% FBS, 2: Fab-Cy5, 3: Fab-Cy5 + 1% FBS
incubated for 12 h, 4: Fab-Cy5 + 1% FBS incubated for 24 h, 5: ﬂuorescence of Fab-Cy5, 6: ﬂuorescence of Fab-Cy5 after incubation with 1% FBS for
12 h, and 7: ﬂuorescence of Fab-Cy5 after incubation with 1% FBS for 24 h).
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Structural and functional studies
Circular dichroism (CD) is a versatile technique to determine
the secondary and tertiary structures of proteins. According to
Fig. 6a, SST, SST-Tetrazine and SST-PEG12 showed typical
random coil structures with a negative band at 201 nm. The
peak at 225 nm of SST is attributed to the presence of a higher
degree of polyproline (PPII) conformation.27
Both native IgG Fab, Fab-Tetrazine and Fab-PEG113 conju-
gates, possess well-defined antiparallel β-pleated sheets con-
firmed by the peaks at 218 nm and 202 nm consistent with the
literature report,23 which confirmed that the secondary struc-
ture of Fab was preserved after modification (Fig. 6b). Next, we
assessed whether the modification of IgG Fab aﬀects its func-
tion to bind to protein L, a bacterial protein known to interact
with Fab fragments of immunoglobulins.28 The binding and
recognition of native Fab and Fab-Tetrazine were thus investi-
gated by enzyme-linked immunosorbent assay (ELISA).
Diﬀerent concentrations (1 nM, 10 nM, 50 nM, 100 nM, and
200 nM) of IgG Fab and Fab-Tetrazine were added to the
protein L coated well plate and incubated for one hour. After
removing the unbound protein, anti-human IgG (Fab specific)-
peroxidase antibody was added to the well plate and incubated
for one hour. Enhanced chemiluminescence solution was
added to the well plate after washing three times with PBS. As
shown in Fig. 6c, the binding aﬃnities between IgG Fab and
Fab-Tetrazine are comparable, suggesting that the binding of
Fab-Tetrazine to protein L was preserved.
Conclusions
Herein, we report a straightforward and broadly applicable bio-
conjugation method for introducing a single tetrazine group
into a targeting peptide and antibody fragment at a pre-
defined, distinct site in aqueous media through disulfide
modification. The tetrazine functionalized peptide or Fab was
further conjugated with a series of TCO-modified functional-
ities, such as dyes, polymers, or proteins/enzymes yielding a
small library of stable bioconjugates within a short reaction
time. Such bulky functionalities could only be introduced by a
two-step procedure as the disulfide rebridging reaction is
greatly limited by the steric demand of the reagent. Bulky sub-
stituents attached to the rebridging reagent such as polymers,
proteins or drug molecules have only limited access to the
reduced disulfide residues resulting in complex product mix-
tures with large amounts of unreacted starting materials and
very low product yield.29 Therefore, the two-step approach pre-
sented herein based on the site-selective installation of the
tetrazine tag first followed by the IEDDA reaction provides con-
venient access to compound libraries, in which a broad range
of small and bulky TCO-modified functionalities could be
attached to the corresponding tetrazine-modified proteins in a
convenient, fast, and eﬃcient way.
Notably, the modified proteins exhibited good stability
under biologically relevant conditions and their secondary
structure was preserved after modification. We envision that
this method would enable the preparation of the desired bio-
conjugates “on site”, e.g. in hospitals for the desired appli-
cations. In this way, the final conjugate would be applied to
the patient immediately after preparation, preventing long
term storage, quality control and loss of bioactivity of the final
conjugate. The approach presented herein is a valuable
addition to the chemical toolbox for site-selective protein lab-
elling and manipulation, oﬀering a fast, robust and straight-
forward method to be easily adapted in any laboratory.
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